Brains Bioceutical Corp. (“Brains” or “Company”) is pleased to announce the completion of a US$31.9 million financing with existing shareholders of DSM Ventureing and Brains. As the main investor in this round, DSM Venture Capital is the corporate venture capital division of Royal DSM (“DSM”). DSM is a science-oriented global company active in health and nutrition. And sustainable living. This landmark investment and strategic transaction strengthens Brains’ position as one of the leading pharmaceutical companies in the cannabinoid (CBD) field. Del Morgan & Co. acted as the financing agent for Brains.
“The completion of the financing marks an exciting milestone for the Brains team. Gaining DSM’s confidence in the next round strengthens Brains’ strategic position in the pharmaceutical industry,” said Brains CEO and Chairman Rick Brar. “The demand for isolated CBD active pharmaceutical ingredients (APIs) in the pharmaceutical and healthcare industry continues to grow. Our team has worked tirelessly to position Brains as the market leader in the CBD industry. Our license suite enables Brains to rapidly expand in Within the industry,” Blair continued.
Pieter Wolters, Managing Director of DSM Ventureing, commented: “The CBD market is growing rapidly, and increasingly strong scientific evidence proves the potential of CBD API in many therapeutic areas. In addition, consumers are increasingly turning to CBD to solve health problems. . Brains’ unparalleled expertise and manufacturing capabilities in the CBD field, coupled with Godsman’s unique scientific and marketing capabilities in the pharmaceutical field, make it an ideal partnership to help pharmaceutical companies realize the early drug development potential of CBD.”
Brains is one of the few companies in the world that produces CBD as an API for drug applications, research, development and clinical trials. It is also one of the few commercial manufacturers in Europe to obtain EU-GMDP certification, producing CBD APIs for human and veterinary use in MHRA-licensed facilities. Brains’ CBD API-its main product to the market-contains 99.7% of CBD and zero tetrahydrocannabinol (THC).
Brains’ progress in developing pure natural CBD benefits the scientific and healthcare communities worldwide. Brains Phytocannabinoid Pure CBD API has successfully passed the test of the INRS laboratory of the World Anti-Doping Agency (WADA). These screening reports confirm that Brains’ CBD API does not contain tetrahydrocannabinol, pesticides, and other prohibited substances listed by WADA. Brains is the first in the industry to obtain such a confirmation of the purity of its CBD and the absence of prohibited substances by a WADA accredited laboratory. WADA has removed CBD from its list of prohibited substances. All activities carried out in the UK are in compliance with British law and are subject to routine and regular inspections by the British authorities.
Brains also launched its branded nutritional supplement CBD “Brains Pure” products in the top health and wellness retail and pharmacy chains in the UK. All Brains products-whether it is the Brains brand or the white label-including a collaboration with a leading British vitamin company, will carry the “Brains Inside®” trademark and provide a seal of quality assurance. Brains is also able to respond well to the strict new food requirements of the British Food Standards Association (FSA) and the European Food Safety Authority (EFSA) for CBD products in the UK. Brains’ collaboration with DSM Ventureing will enable the company to leverage the strategic partnership that DSM has established since its initial establishment in 1902.
About Brain Biopharmaceutical Company.
Brains Bioceutical Corp. is a leader in the production of natural active pharmaceutical ingredients (API) in the pharmaceutical and nutraceutical industry that is GMP certified by the European Union. Brains Bioceutical is one of the only manufacturers of natural phytocannabinoid active pharmaceutical ingredients (API) in commercial production today, and has participated in global academic and clinical trials. Brains’ senior management team is composed of rare pharmaceutical and consumer product executives. They have held executive and other senior positions in companies such as GW Pharma, Merck, Danone, Earthbound Farms, International Herbs, Cascadia Specialties, and The Royal Navy. Brains is in British wholly-owned subsidiary BSPG Laboratories is one of the few companies with commercial capabilities and EU-GMDP certification to produce CBD API.
About DSM Entrepreneurship
DSM Ventureing is the corporate venture capital arm of Royal DSM. Royal DSM is a global, goal-oriented, science-based company active in nutrition, health and sustainable living. DSM’s mission is to create a better life for everyone. DSM uses its products and solutions to address some of the world’s greatest challenges, while creating economic, environmental and social value for all stakeholders-customers, employees, shareholders and society as a whole. DSM provides innovative solutions for human nutrition, animal nutrition, personal care and aroma, medical equipment, green products and applications, and new mobility and connectivity. DSM and its affiliates have approximately 23,000 employees and annual net sales of approximately EUR 10 billion. The company was founded in 1902 and listed on Euronext Amsterdam.
More information can be found at www.dsm.com/venturing.
This press release contains forward-looking statements or forward-looking information within the meaning of securities laws (“forward-looking statements”). Usually, but not always, forward-looking statements can be made through the use of “plans”, “expects” or “unexpected”, “anticipates”, “estimates”, “intends”, “expects” or “unexpected Believe”, or variations of such words and phrases, or state that certain actions, events or results “may”, “may”, “will”, “may” or “will” occur or be achieved. All statements in this press release other than statements of historical facts are forward-looking statements and are based on expectations, estimates and forecasts on the date of this press release. Any statements that involve discussions about predictions, expectations, beliefs, plans, forecasts, goals, assumptions, future events or performance are not statements of historical facts and may be forward-looking statements. The risks, uncertainties and other factors involved in forward-looking statements may cause actual events, results, performance, prospects and opportunities to be materially different from those expressed or implied in such forward-looking statements. Although the company believes that the assumptions and factors used in the preparation of forward-looking statements in this press release are reasonable, it cannot guarantee that such statements will prove to be accurate because actual results and future events may differ materially from expectations. In the statement. Readers should not place undue reliance on the forward-looking statements and information contained in this press release. The forward-looking statements contained in this press release were made on the date of this press release. Unless applicable securities requirements, the company assumes no obligation to publicly update such forward-looking statements to reflect new information, subsequent events, or other circumstances. .